Anti-GPR161 monoclonal antibody

Pre-made anti-GPR161 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to GPR161/GPR161 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP0937-Ab-1/ GM-Tg-hg-IP0937-Ab-2Anti-Human GPR161 monoclonal antibodyHuman
GM-Tg-rg-IP0937-Ab-1/ GM-Tg-rg-IP0937-Ab-2Anti-Rat GPR161 monoclonal antibodyRat
GM-Tg-mg-IP0937-Ab-1/ GM-Tg-mg-IP0937-Ab-2Anti-Mouse GPR161 monoclonal antibodyMouse
GM-Tg-cynog-IP0937-Ab-1/ GM-Tg-cynog-IP0937-Ab-2Anti-Cynomolgus/ Rhesus macaque GPR161 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP0937-Ab-1/ GM-Tg-felg-IP0937-Ab-2Anti-Feline GPR161 monoclonal antibodyFeline
GM-Tg-cang-IP0937-Ab-1/ GM-Tg-cang-IP0937-Ab-2Anti-Canine GPR161 monoclonal antibodyCanine
GM-Tg-bovg-IP0937-Ab-1/ GM-Tg-bovg-IP0937-Ab-2Anti-Bovine GPR161 monoclonal antibodyBovine
GM-Tg-equg-IP0937-Ab-1/ GM-Tg-equg-IP0937-Ab-2Anti-Equine GPR161 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP0937-Ab-1/ GM-Tg-hg-IP0937-Ab-2; GM-Tg-rg-IP0937-Ab-1/ GM-Tg-rg-IP0937-Ab-2;
GM-Tg-mg-IP0937-Ab-1/ GM-Tg-mg-IP0937-Ab-2; GM-Tg-cynog-IP0937-Ab-1/ GM-Tg-cynog-IP0937-Ab-2;
GM-Tg-felg-IP0937-Ab-1/ GM-Tg-felg-IP0937-Ab-2; GM-Tg-cang-IP0937-Ab-1/ GM-Tg-cang-IP0937-Ab-2;
GM-Tg-bovg-IP0937-Ab-1/ GM-Tg-bovg-IP0937-Ab-2; GM-Tg-equg-IP0937-Ab-1/ GM-Tg-equg-IP0937-Ab-2
Products NameAnti-GPR161 monoclonal antibody
Formatmab
Target NameGPR161
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-GPR161 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP0937-Ag-1Recombinant multi-species GP161/ GPR161/ RE2 protein
    ORF Viral VectorpGMLV000353human GPR161 Lentivirus plasmid
    ORF Viral VectorpGMLP003154human GPR161 Lentivirus plasmid
    ORF Viral VectorvGMLP003154human GPR161 Lentivirus particle
    ORF Viral VectorvGMLV000353human GPR161 Lentivirus particle


    Target information

    Target IDGM-IP0937
    Target NameGPR161
    Gene ID23432,240888,289180,698934,490358,101100357,768006,100051574
    Gene Symbol and SynonymsGm208,Gm208Gpr,GPR161,RE2,RGD1563245,vl
    Uniprot AccessionQ8N6U8,Q2YDN1
    Uniprot Entry NameGP161_HUMAN,GP161_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000143147
    Target ClassificationN/A

    The target: GPR161, gene name: GPR161, also named as RE2. The protein encoded by this gene is an orphan G protein-coupled receptor whose ligand is unknown. This gene is overexpressed in triple-negative breast cancer, and disruption of this gene slows the proliferation of basal breast cancer cells. Therefore, this gene is a potential drug target for triple-negative breast cancer. [provided by RefSeq, Mar 2017].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.